Recent developments in prophylaxis and therapy of invasive fungal infections in granulocytopenic cancer patients

Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients

This report focuses on the value of antifungal prophylaxis with antifungal drugs in preventing oropharyngeal candidiasis. Randomised trials comparing non-AIDS immunocompromised patients receiving or not an oral antifungal agent were reviewed. Colonisation of the throat with Candida albicans is a risk factor, principally when cultures for this species of yeasts remain positive after initiation of the prophylaxis. The results of the trials were meta-analysed and we obtained a combined odds ratio for developing oropharyngeal candidiasis of 0.15 when under antifungal prophylaxis (confidence interval at 95%:0.10-0.22, chi 2 statistic of 90.77, P < 0.0001). We conclude that there is a strong beneficial effect of antifungal prophylaxis against the occurrence of oropharyngeal candidiasis. However, up to now, no study has correctly assessed the value of nystatin as a prophylactic agent against oropharyngeal candidiasis.

Lethal infections in patients with hematological malignancies

The hospital files of 410 patients with hematological malignancy treated at our clinic between 1977 and 1990 were reviewed to determine the importance of infections as a cause of death. The total number of infections was 203 (49.5%). A microbiologically documented infection was detected in 27.3%, a clinically documented infection in 9.5% and a possible infection in 12.7% of the patients. Gram-positive bacteria were responsible for 25.9%, gram-negative bacteria for 31.3%, anaerobic bacteria for 2.7%, viruses for 4.5% and fungi for 25.9% of the microbiologically documented infections. Of 29 systemic fungal infections only 2 were diagnosed before the patients died. The remaining diagnoses rested on autopsy findings. Empiric antifungal therapy was introduced in 1983; still, 74.2% of systemic fungal infections in 1977-1990 were detected after 1982. Patients with a verified infection had statistically significantly higher CRP concentrations than patients who died of other causes (152 mg/l vs. 117.5 mg/l, p = 0.018). We conclude that infection is a significant cause of death in patients with these diseases. The number of systemic fungal infections is increasing, despite the widespread use of antifungal medication and thus better diagnostic methods and more effective treatment are needed.

Fungal infections during neutropenia: the role of prophylaxis

Fungal infections are seen predominantly in patients with neoplastic diseases. Autopsy studies revealed that 30 to 50% of decreased patients with hematologic neoplasms have histopathologically documented invasive fungal infections. The rationale for fungal chemoprophylaxis is the high incidence of fungal disease in these patients (5), the high mortality (29), the difficulty in diagnosing (28), and the severe side effects of systemic antifungal therapy with amphotericin B (3). Endogenous sources such as oropharyngeal and digestive mucous membranes and exogenous pathways such as air (e.g.aspergilli) or food have to be considered. Therefore, prophylaxis has to comprise both aspects:Prevention of acquisition through nonspecific hygiene measures (5), reduction of colonization (non-absorbable antifungals or systemic chemoprophylaxis) (20). Antifungal prophylaxis of candidosis with both non- and absorbable drugs has not been convincing in terms of reduction of proven fungal infections. Prevention of aspergillosis consists mainly of the control of room air.